Herantis Pharma's Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program
Herantis Pharma's Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program Herantis Pharma PlcCompany release 12 Dec 2016 at 9:00 am The research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for Herantis Pharma Plc's ("Herantis") Phase 1-2 clinical study with Herantis' drug candidate CDNF for the treatment of Parkinson's disease ("PD"), using an innovative drug administration device of Renishaw plc; and for supporting scientific research. With the grant Herantis expects its financial